Logo

50
issue
50 (145) 2021

Interviews

Green transformation - the pandemic's biggest beneficiary

Header witold or owski 1
Prof Witold Orłowski, PwC Polska's chief economic advisor, talks to the BPCC's Michael Dembinski about how Covid-19 is reshaping trends in the global economy


How concerned are you by the sharp rise in inflation, in Poland, Europe and globally? Is the Polish government prepared to use monetary policy to tackle inflation? Are there any factors in the global economy that might naturally slow down inflation, or should we get used to rising prices – and wages – for the foreseeable future?

Read more

More in Interviews:

Interviews

Addressing post-pandemic challenges facing the healthcare system

Anna Rulkiewicz, CEO of Lux Med, talks to the BPCC’s Michael Dembinski about the pressing need for cooperation between the private healthcare sector and the state if Poland is to meet the healthcare needs of its population


From the macroeconomic perspective, we have seen how the percentage of GDP countries spend on healthcare has increased because of the pandemic. Poland’s share rose from 6.5% in 2019 to 7.2% in 2020, whilst the UK increased its share from 10.2% to 12.8%. The disparity between the UK and other OECD countries and Poland shows that there’s still a big gap to be filled. [Of EU member states in the OECD, only Hungary spends less.] Which measures should the Polish government take to improve the access to and quality of its healthcare system in the long term?

Interviews

Lesson One: Don’t forget what the pandemic has taught you!

Marc Burrage, managing director of Hays Poland, talks to the BPCC’s Michael Dembinski about the impact of Covid on the world of work, and how Poland is placed to do well from the recovery.


We are now approaching the second anniversary of the Covid-19 outbreak in the world. How has the Polish labour market reacted to the pandemic?

Interviews

A sense of responsibility for the people’s lives and health during a pandemic

Wiktor Janicki, country president, AstraZeneca Pharma Poland, talks to the BPCC’s Michael Dembinski about the vital importance of R&D for the future of healthcare and Poland’s role in developing future therapies.


AstraZeneca has been in Poland for 30 years – it was one of the founding members of the BPCC. Since then, it has expanded its activities from just selling medicines to becoming a major R&D site for AstraZeneca, employing in total over 2,300 people here. What factors led to Poland becoming such a good location for growth over that time?